208719
ALLN
≥95% (HPLC), solid, calpain inhibitor, Calbiochem®
别名:
ALLN, LLNL，MG 101，钙蛋白酶抑制剂I，蛋白酶体抑制剂V
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H37N3O4
化学文摘社编号:
分子量:
383.53
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
ALLN, Cell-permeable inhibitor of calpain I (Ki = 190 nM), calpain II (Ki = 220 nM), cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM).
SMILES string
N([C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C=O)C(=O)[C@@H](NC(=O)C)CC(C)C
InChI
1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1
InChI key
FMYKJLXRRQTBOR-BZSNNMDCSA-N
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white to off-white
solubility
DMSO: 10 mg/mL
ethanol: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
针对钙蛋白酶I、钙蛋白酶II、组织蛋白酶B和组织蛋白酶L分别为190 nM、220 nM、150 nM、500 pM
主要靶标
钙蛋白酶I
钙蛋白酶I
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
Disclaimer
毒性：标准处理（A）
General description
钙蛋白酶I（Ki=190 nM），钙蛋白酶II（Ki=220 nM），组织蛋白酶B（Ki=150 nM）和组织蛋白酶L（Ki=500 pM）的抑制剂。抑制中性半胱氨酸蛋白酶和蛋白酶体（Ki = 6 µM）。防止缺氧和缺血引起的神经元损伤。抑制胸腺细胞和晚幼粒细胞中的凋亡。通过抑制细胞周期蛋白B降解，抑制CHO细胞中G1/S边界和中期/后期的细胞周期进程。还可以通过干扰诱导型一氧化氮合酶基因的转录来防止活化巨噬细胞产生一氧化氮。抑制泛素-蛋白酶体复合物对IκBα和IκBβ的蛋白水解作用。
钙蛋白酶I（Ki=190 nM），钙蛋白酶II（Ki=220 nM），组织蛋白酶B（Ki=150 nM）和组织蛋白酶L（Ki=500 pM）的细胞可渗透抑制剂。抑制中性半胱氨酸蛋白酶和蛋白酶体（Ki = 6 µM）。调节β-淀粉样前体蛋白（βAPP）至β-淀粉样蛋白（Aβ）的加工。防止缺氧和缺血引起的神经元损伤。抑制胸腺细胞和晚幼粒细胞中的凋亡。还抑制L929细胞中呼肠孤病毒诱导的凋亡。抑制泛素-蛋白酶体复合物对IκBα和IκBβ的蛋白水解作用。通过抑制细胞周期蛋白B降解，抑制CHO细胞G1/S和中期/后期的细胞周期进程。还可以通过干扰诱导型一氧化氮合酶基因的转录来防止活化巨噬细胞产生一氧化氮。也可购买10 mM（5 mg/1.30 ml）ALLN的DMSO溶液（目录号208750）。
Other Notes
Debiasi, R.L., et al. 1999.J. Virol.73, 695.
Zhang, L., et al. 1999.J. Biol. Chem.274, 8966.
Milligan, S.A., et al. 1996.Arch.Biochem.Biophys.335, 388.
Griscavage, J.M., et al. 1995.Biochem.Biophys.Res. Commun.215, 721.
Squier, M.K., et al. 1994.J. Cell Physiol.159, 229.
Rami, J., and Kreiglstein, J. 1993.Brain Res.609, 67.
Sherwood, S.W., et al. 1993.Proc.Natl.Acad.Sci.USA90, 3353.
Vinitsky, A., et al. 1992.Biochemistry31, 9421.
Sasaki, T., et al. 1990.J. Enzyme Inhib.3, 195.
Zhang, L., et al. 1999.J. Biol. Chem.274, 8966.
Milligan, S.A., et al. 1996.Arch.Biochem.Biophys.335, 388.
Griscavage, J.M., et al. 1995.Biochem.Biophys.Res. Commun.215, 721.
Squier, M.K., et al. 1994.J. Cell Physiol.159, 229.
Rami, J., and Kreiglstein, J. 1993.Brain Res.609, 67.
Sherwood, S.W., et al. 1993.Proc.Natl.Acad.Sci.USA90, 3353.
Vinitsky, A., et al. 1992.Biochemistry31, 9421.
Sasaki, T., et al. 1990.J. Enzyme Inhib.3, 195.
N-Acetyl-Leu-Leu-Nle-CHO
Preparation Note
复溶后，等分并冷冻保存（-20°C）。储备液在-20°C条件下可稳定保存6个月。
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Jin-Kai Wang et al.
Circulation, 145(9), 675-687 (2022-02-23)
High blood cholesterol accelerates the progression of atherosclerosis, which is an asymptomatic process lasting for decades. Rupture of atherosclerotic plaques induces thrombosis, which results in myocardial infarction or stroke. Lowering cholesterol levels is beneficial for preventing atherosclerotic cardiovascular disease. Low-density
J Michael Younger et al.
Methods in molecular biology (Clifton, N.J.), 301, 293-303 (2005-05-27)
Components of the ubiquitin-proteasome system function on the surface of the endoplasmic reticulum (ER) to select misfolded proteins for degradation. Herein we describe methods that allow for the study of the pathway for proteasomal degradation of the cystic fibrosis transmembrane
Abdallah Mound et al.
PloS one, 18(1), e0279028-e0279028 (2023-01-21)
Nod-Like Receptor Pyrin domain-containing protein 6 (NLRP6), a member of the Nucleotide-oligomerization domain-Like Receptor (NLR) family of proteins, assembles together with the ASC protein to form an inflammasome upon stimulation by bacterial lipoteichoic acid and double-stranded DNA. Besides its expression
Yi-Hsin Liang et al.
Journal of biomedical science, 28(1), 75-75 (2021-11-12)
A new strategy, particularly a novel combination, for immunotherapy in microsatellite stable metastatic colorectal cancer (mCRC) treatment needs to be formulated. Studies on the interferon-γ (IFN-γ)/ Janus kinase (JAK)/ signal transducer and activator of transcription (STAT)1 pathway provide new directions
Yuhang Shi et al.
Viruses, 15(9) (2023-09-28)
SERINC5 is a restriction factor that becomes incorporated into nascent retroviral particles, impairing their ability to infect target cells. In turn, retroviruses have evolved countermeasures against SERINC5. For instance, the primate lentiviruses (HIV and SIV) use Nef, Moloney Murine Leukemia
相关内容
Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持